STORM in the News
Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. Drug Discovery World’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.
Read more
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting set the agenda for oncology research, with cutting-edge research into topics as diverse as immunotherapy, the latest small molecule trials, and the growing role of AI in drug development.
Read more
STC15 is Storm Therapeutics' first-in-class, and first-to-clinic inhibitor of the post-transcriptional RNA modifier METTL3, which progressed from HTS hit to clinical development in less than three years. Targeting RNA has been of significant recent interest, catalyzed in part by the clinical success of small-molecule RNA splicing modifiers.
Read more
From 5-10 April 2024 in San Diego, the cancer research community gathered for the annual meeting of the American Association for Cancer Research (AACR). DDW’s Megan Thomas spoke with biotech and pharma leaders to understand more about the cancer research landscape.
Read more
Watch Jerry McMahon, CEO of STORM Therapeutics, speaking in Optimum Strategic Communications’ latest edition of Optimum TV where he discusses the Company’s approach to cellular reprogramming through RNA modification and why STORM is leading the field in this area.
Read more